These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 21387286)

  • 61. Structure of natural killer cell receptor KLRG1 bound to E-cadherin reveals basis for MHC-independent missing self recognition.
    Li Y; Hofmann M; Wang Q; Teng L; Chlewicki LK; Pircher H; Mariuzza RA
    Immunity; 2009 Jul; 31(1):35-46. PubMed ID: 19604491
    [TBL] [Abstract][Full Text] [Related]  

  • 62. KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer.
    Muraro E; De Zorzi M; Miolo G; Lombardi D; Scalone S; Spazzapan S; Massarut S; Perin T; Dolcetti R; Steffan A; De Re V
    Front Immunol; 2021; 12():791958. PubMed ID: 35095867
    [TBL] [Abstract][Full Text] [Related]  

  • 63. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
    Gerdes CA; Nicolini VG; Herter S; van Puijenbroek E; Lang S; Roemmele M; Moessner E; Freytag O; Friess T; Ries CH; Bossenmaier B; Mueller HJ; Umaña P
    Clin Cancer Res; 2013 Mar; 19(5):1126-38. PubMed ID: 23209031
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.
    Bruckheimer EM; Fazenbaker CA; Gallagher S; Mulgrew K; Fuhrmann S; Coffman KT; Walsh W; Ready S; Cook K; Damschroder M; Kinch M; Kiener PA; Woods R; Gao C; Dall'Acqua W; Wu H; Coats S
    Neoplasia; 2009 Jun; 11(6):509-17, 2 p following 517. PubMed ID: 19484140
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Molecular basis for E-cadherin recognition by killer cell lectin-like receptor G1 (KLRG1).
    Nakamura S; Kuroki K; Ohki I; Sasaki K; Kajikawa M; Maruyama T; Ito M; Kameda Y; Ikura M; Yamamoto K; Matsumoto N; Maenaka K
    J Biol Chem; 2009 Oct; 284(40):27327-35. PubMed ID: 19654330
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Anti-HER2 Cancer-Specific mAb, H
    Suzuki H; Ohishi T; Tanaka T; Kaneko MK; Kato Y
    Int J Mol Sci; 2024 Aug; 25(15):. PubMed ID: 39125956
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines.
    Collins DM; O'Donovan N; McGowan PM; O'Sullivan F; Duffy MJ; Crown J
    Ann Oncol; 2012 Jul; 23(7):1788-95. PubMed ID: 22056974
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma.
    Mimura K; Kono K; Hanawa M; Kanzaki M; Nakao A; Ooi A; Fujii H
    Clin Cancer Res; 2005 Jul; 11(13):4898-904. PubMed ID: 16000588
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.
    Muraro E; Comaro E; Talamini R; Turchet E; Miolo G; Scalone S; Militello L; Lombardi D; Spazzapan S; Perin T; Massarut S; Crivellari D; Dolcetti R; Martorelli D
    J Transl Med; 2015 Jun; 13():204. PubMed ID: 26116238
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells.
    Karagiannis P; Singer J; Hunt J; Gan SK; Rudman SM; Mechtcheriakova D; Knittelfelder R; Daniels TR; Hobson PS; Beavil AJ; Spicer J; Nestle FO; Penichet ML; Gould HJ; Jensen-Jarolim E; Karagiannis SN
    Cancer Immunol Immunother; 2009 Jun; 58(6):915-30. PubMed ID: 18941743
    [TBL] [Abstract][Full Text] [Related]  

  • 71. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
    El-Sahwi K; Bellone S; Cocco E; Cargnelutti M; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2010 Jan; 102(1):134-43. PubMed ID: 19920829
    [TBL] [Abstract][Full Text] [Related]  

  • 72. PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity.
    Du R; Zhang X; Lu X; Ma X; Guo X; Shi C; Ren X; Ma X; He Y; Gao Y; Liu Y
    Drug Resist Updat; 2023 May; 68():100947. PubMed ID: 36812747
    [TBL] [Abstract][Full Text] [Related]  

  • 73. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
    Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells.
    Köninki K; Barok M; Tanner M; Staff S; Pitkänen J; Hemmilä P; Ilvesaro J; Isola J
    Cancer Lett; 2010 Aug; 294(2):211-9. PubMed ID: 20193978
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Trastuzumab, a monoclonal anti-HER2 antibody modulates cytotoxicity against cholangiocarcinoma via multiple mechanisms.
    Panaampon J; Sungwan P; Fujikawa S; Sampattavanich S; Jirawatnotai S; Okada S
    Int Immunopharmacol; 2024 Sep; 138():112612. PubMed ID: 38968862
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy.
    Fujimoto-Ouchi K; Sekiguchi F; Yamamoto K; Shirane M; Yamashita Y; Mori K
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):269-76. PubMed ID: 19904537
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer.
    Liikanen I; Tähtinen S; Guse K; Gutmann T; Savola P; Oksanen M; Kanerva A; Hemminki A
    Mol Cancer Ther; 2016 Sep; 15(9):2259-69. PubMed ID: 27458139
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients.
    Petricevic B; Laengle J; Singer J; Sachet M; Fazekas J; Steger G; Bartsch R; Jensen-Jarolim E; Bergmann M
    J Transl Med; 2013 Dec; 11():307. PubMed ID: 24330813
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
    Collins DM; Gately K; Hughes C; Edwards C; Davies A; Madden SF; O'Byrne KJ; O'Donovan N; Crown J
    Cell Immunol; 2017 Sep; 319():35-42. PubMed ID: 28735814
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Generation and preclinical characterization of an NKp80-Fc fusion protein for redirected cytolysis of natural killer (NK) cells against leukemia.
    Deng G; Zheng X; Zhou J; Wei H; Tian Z; Sun R
    J Biol Chem; 2015 Sep; 290(37):22474-84. PubMed ID: 26198633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.